Latest Conference Coverage


Shadi Yaghi, MD

Anticoagulation Reduces Risk of Stroke in Cervical Artery Dissection, With Effects Based on Timing

February 13th 2024

A recent study showed anticoagulation reduced ischemic stroke risk in patients with cervical artery dissection; however, cautioned is warned about the importance of transitioning to antiplatelet therapy at a certain point.


Anti-Inflammatory Agent RNS60 Demonstrates Robust Impact on Poststroke Disability in Phase 2 RESCUE Study

Anti-Inflammatory Agent RNS60 Demonstrates Robust Impact on Poststroke Disability in Phase 2 RESCUE Study

February 13th 2024

Topline results from the RESCUE trial indicate that RNS60, an anti-inflammatory agent, demonstrates safety and potential efficacy in acute ischemic stroke.


Insights on the EMBOLISE Trial and Advancing Treatment for Subdural Hematoma: Jason M. Davies, MD, PhD

Insights on the EMBOLISE Trial and Advancing Treatment for Subdural Hematoma: Jason M. Davies, MD, PhD

February 12th 2024

The assistant professor of neurosurgery and biomedical informatics at the State University of New York at Buffalo provided commentary on the significant findings from the EMBOLISE trial presented at the 2024 International Stroke Conference. [WATCH TIME: 4 minutes]


AI-Based Support System Provides Significant Benefits to Stroke Care

AI-Based Support System Provides Significant Benefits to Stroke Care

February 12th 2024

Using a cohort of more than 20,000 patients with ischemic stroke, those on AI-CDSS experienced less vascular events of hemorrhagic stroke, myocardial infarction, or vascular death.


Poststroke Neurologic Deterioration Reduced With Tirofiban, Study Finds

Poststroke Neurologic Deterioration Reduced With Tirofiban, Study Finds

February 10th 2024

Tirofiban treatment in acute ischemic stroke reduced early neurological deterioration compared to oral antiplatelet therapy alone, warranting further investigation.


Increased Levels of Neurofilament Light and GFAP Confirmed During Acute Stroke

Increased Levels of Neurofilament Light and GFAP Confirmed During Acute Stroke

February 9th 2024

Elezanumab's biomarker analysis in stroke patients underscores its potential as a neuroprotective therapy for acute ischemic stroke management.


Fibrinogenase Injection Improves Functional Outcome Following Ischemic Stroke

Fibrinogenase Injection Improves Functional Outcome Following Ischemic Stroke

February 9th 2024

Over a 90-day period, investigators observed significantly lower functional outcomes on modified Rankin Scale and similar rates of bleeding and death when compared with control.


Santosh Murthy, MD, MPH

A National Registry Analysis on Minimally Invasive Surgery for Intracerebral Hemorrhage: Santosh Murthy, MD, MPH

February 8th 2024

The associate professor of neurology at Weill Cornell Medicine talked about a recent study that revealed that minimally invasive surgery significantly reduced the risk of mortality in patients with nontraumatic intracerebral hemorrhage. [WATCH TIME: 4 minutes]


Innovative Approaches and Treatment Inventions for Stroke Care at ISC 2024: Babak Navi, MD, MS

Innovative Approaches and Treatment Inventions for Stroke Care at ISC 2024: Babak Navi, MD, MS

February 7th 2024

The chief of the division of stroke and hospital neurology at Weill Cornell Medicine shared some of his thoughts on the promising clinical trials being presented at the 2024 International Stroke Conference. [WATCH TIME: 3 minutes]


Adrenomedullin Safe to Treat Ischemic Stroke, May Lead to Improved Outcomes

Adrenomedullin Safe to Treat Ischemic Stroke, May Lead to Improved Outcomes

February 7th 2024

In comparison with placebo, slightly better outcomes on modified Rankin Scale were observed with adrenomedullin.


Patricia C. Dugan, MD

Narrowing the Treatment Gap and Raising Awareness of Surgical Options for Epilepsy: Patricia C. Dugan, MD

February 6th 2024

The associate professor of neurology at NYU Grossman School of Medicine talked about the need for increased awareness in the medical community to address the underutilization of surgical interventions for refractory focal epilepsy. [WATCH TIME: 4 minutes]


Emphasizing Shared Decision Making and Emerging Strategies in MS Treatment: Patricia K. Coyle, MD

Emphasizing Shared Decision Making and Emerging Strategies in MS Treatment: Patricia K. Coyle, MD

February 5th 2024

The professor of neurology at Stony Brook University Medical Center discussed the significance of shared decision making in multiple sclerosis care and promising developments in treatment strategies. [WATCH TIME: 3 minutes]


A Conversation on Women's Leadership and Career in Medicine: Jennifer Frontera, MD

A Conversation on Women's Leadership and Career in Medicine: Jennifer Frontera, MD

February 3rd 2024

The professor of neurology at NYU Grossman School of Medicine talked about the importance of aligning leadership roles with personal passions for women in the field of neurology pursuing their careers in medicine. [WATCH TIME: 5 minutes]


Matthew Schrag, MD, PhD

The Next Wave of Stroke Care Beyond the Acute Phase: Matthew Schrag, MD, PhD

February 2nd 2024

The associate professor of neurology at Vanderbilt University Medical Center discussed exploring promising opportunities in other phases outside of the acute phase of ischemic stroke. [WATCH TIME: 3 minutes]


Iryna Leunikava, MSc

Insights on Seizure Therapy and Future Plans in Epilepsy Research: Iryna Leunikava, MSc

January 25th 2024

The European evidence generation strategy lead for epilepsy and rare syndromes at UCB described some details about further epilepsy research and other explorations in the next few years. [WATCH TIME: 3 minutes]


Derek Ems, MPH, CPHQ

Enhancing Methodologies for Comprehensive Patient Outcome Analysis in Epilepsy: Derek Ems, MPH, CPHQ

January 25th 2024

The health economics outcomes research specialist at UCB discussed the need for improved methodologies to have a more accurate analysis of patient outcomes beyond what administrative databases can provide. [WATCH TIME: 2 minutes]


Jude Luker, BA (Hons), head of Patient Engagement, Epilepsy and Rare Syndromes (Europe) at UCB Pharma

The Urgent Need for Improved Physician-Patient Conversations on SUDEP: Jude Luker, BA (Hons)

January 24th 2024

The head of Patient Engagement, Epilepsy and Rare Syndromes (Europe) at UCB Pharma discussed the inconsistencies in educational information given to patients with epilepsy, including the knowns of sudden unexpected death. [WATCH TIME: 4 minutes]


Jude Luker, BA (Hons), head of Patient Engagement, Epilepsy and Rare Syndromes (Europe) at UCB Pharma

Raising Discussion on Gaps in SUDEP Knowledge in Epilepsy Care: Jude Luker, BA (Hons)

January 17th 2024

The head of Patient Engagement, Epilepsy and Rare Syndromes (Europe) at UCB Pharma discussed findings from a literature review presented at AES 2023 involving conversations about sudden unexpected death in epilepsy. [WATCH TIME: 4 minutes]


A Neurological Perspective on Lessons from the COVID-19 Pandemic in NMOSD: Lorna Galleguillos, MD; Ricardo Alonso MD, MSc

A Neurological Perspective on Lessons from the COVID-19 Pandemic in NMOSD: Lorna Galleguillos, MD; Ricardo Alonso MD, MSc

January 9th 2024

The neuroimmunologist at Clínica Alemana de Santiago and head of the University Center for Multiple Sclerosis at Ramos Mejía Hospital discussed Latin American efforts to understand neuromyelitis optica spectrum disorder during the COVID-19 pandemic. [WATCH TIME: 5 minutes]


Addressing the Unmet Needs of Managing MS Symptoms: Michael Y. Sy, MD, PhD

Addressing the Unmet Needs of Managing MS Symptoms: Michael Y. Sy, MD, PhD

January 8th 2024

The associate professor of clinical neurology at University of California, Irvine School of Medicine talked about addressing the critical unmet needs in disability progression among patients with multiple sclerosis. [WATCH TIME: 3 minutes]


Pathing the Next Steps in Alzheimer Disease Research: Heather Snyder, PhD

Pathing the Next Steps in Alzheimer Disease Research: Heather Snyder, PhD

January 8th 2024

The vice president of medical and scientific relations at the Alzheimer’s Association discussed where the organization’s efforts are currently invested and the ways to continue momentum in the Alzheimer disease field. [WATCH TIME: 5 minutes]


Neurologist’s Role in Addressing Healthcare Disparities: A. Gordon Smith, MD, FAAN

Neurologist’s Role in Addressing Healthcare Disparities: A. Gordon Smith, MD, FAAN

January 7th 2024

The professor and chair of neurology at Virginia Commonwealth University discussed how neurologists are urged to take organized action and provide training on healthcare disparities, with a particular focus on race, ethnicity, and financial barriers to access. [WATCH TIME: 2 minutes]


Exploring the Efficacy and Evidence of Efgartigimod as a Potential Therapy for CIDP: Richard Lewis, MD

Exploring the Efficacy and Evidence of Efgartigimod as a Potential Therapy for CIDP: Richard Lewis, MD

January 5th 2024

The professor of neurology at Cedars-Sinai Medical Center talked about efgartigimod as a novel treatment for chronic inflammatory demyelinating polyneuropathy, with the potential of it being a first-line treatment for patients with the condition. [WATCH TIME: 3 minutes]


Rett Syndrome Symptoms and Quality of Life Improvements Through Trofinetide: Ponni Subbiah, MD, MPH

Rett Syndrome Symptoms and Quality of Life Improvements Through Trofinetide: Ponni Subbiah, MD, MPH

December 21st 2023

The chief medical officer of Acadia Pharmaceuticals provided commentary on a caregiver analysis assessing beneficial experiences with trofinetide in patients with Rett syndrome. [WATCH TIME: 4 minutes]


Management of Focal Onset Seizures With Brivaracetam Adjunctive Therapy: Iryna Leunikava, MSc

Management of Focal Onset Seizures With Brivaracetam Adjunctive Therapy: Iryna Leunikava, MSc

December 21st 2023

The European evidence generation strategy lead for epilepsy and rare syndromes at UCB Pharma talked about positive results from observational studies assessing the impact of brivaracetam among patients with focal seizures, which was presented at AES 2023. [WATCH TIME: 5 minutes]


NeuroVoices: Ponni Subbiah, MD, MPH, on the Open-Label LILAC-2 Study of Trofinetide

NeuroVoices: Ponni Subbiah, MD, MPH, on the Open-Label LILAC-2 Study of Trofinetide

December 20th 2023

The senior vice president, global head of medical affairs, and chief medical officer at Acadia Pharmaceutical, gave an overview of LILAC-2, a long-term extension study assessing trofinetide (Daybue), the first approved therapy for Rett syndrome.

© 2024 MJH Life Sciences

All rights reserved.